You’re using a public version of DrugChatter with 1 free searches available. Register to unlock more free searches per day. CREATE FREE ACCOUNT

Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

Is lacosamide safe for extended use?



Lacosamide is an antiepileptic drug used to treat partial-onset seizures in adults with epilepsy. The drug works by stabilizing electrical activity in the brain. According to the sources provided, Lacosamide is considered safe for extended use in the treatment of epilepsy [2][3].

The patent for Lacosamide expired in 2018, making it available as a generic drug. It has been approved by the FDA for long-term use in the United States [1].

A study published in the Journal of Clinical Neurology evaluated the safety and efficacy of Lacosamide as an add-on therapy for patients with epilepsy. The study found that Lacosamide was generally well-tolerated, and no significant safety concerns were identified [2].

According to epilepsy.com, the most common side effects of Lacosamide are dizziness, headache, and nausea. However, these side effects are generally mild and do not require treatment [3].

In conclusion, Lacosamide is considered safe for extended use in the treatment of epilepsy. It has been approved by the FDA for long-term use and has been found to be generally well-tolerated with no significant safety concerns identified in clinical studies. However, as with any medication, patients should be aware of potential side effects and discuss any concerns with their healthcare provider.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LACOSAMIDE
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8408586/
[3] https://www.epilepsy.com/medications/lacosamide



Follow-up:   What are the long-term effects of lacosamide? Has lacosamide been tested for prolonged use? Are there any known risks associated with lacosamide use?





DrugPatentWatch - Make Better Decisions
© thinkBiotech LLC 2004 - 2024. All rights reserved.